| 规格: | 98% |
| 分子量: | 845 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
Background:
Cabazitaxel-d9 is intended for use as an internal standard for the quantification of cabazitaxel by GC- or LC-MS. Cabazitaxel is a second generation semisynthetic taxane derived from 10-deacetylbaccatin III .1 It stabilizes microtubule assembly by reducing lag time for tubulin assembly (LT50 = 100 nM) and the rate of cold-induced microtubule depolymerization (IC50s = 100-250 nM) in vitro. Cabazitaxel inhibits proliferation of P388, HL-60, Calc18, and KB cells (IC50s = 4-41 nM), as well as P-glycoprotein-expressing, drug-resistant versions of these cell lines (IC50s = 16-414 nM). In vivo, cabazitaxel dose-dependently reduces tumor growth in docetaxel-susceptible N87 human gastric carcinoma and docetaxel-resistant UISO BCA-1 breast cancer mouse xenograft models. Formulations containing cabazitaxel have been used in combination with prednisone in the treatment of hormone-refractory metastatic prostate cancer.
参考文献
1. Vrignaud, P., S?miond, D., Lejeune, P., et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin. Cancer Res. 19(11), 2973-2983 (2013).
m.cnreagent.com
